A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

NCT01349036 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Recurrent Glioblastoma

Interventions

DRUG: PLX3397

Sponsor

Daiichi Sankyo

Collaborators

[object Object]